Craig Zinderman, MD, MPH

Zinderman tells Baer he has no issue with Szarfman's VAERS access through Empirica.

Baer questions Szarfman's COVID vaccine data mining; Zinderman cautions against blocking access.

Baer acknowledges Szarfman knows more about data mining but characterizes her comments as atypical.

Niu writes Baer that she and Zinderman will meet with Szarfman about her VAERS objectives.

Szarfman shares DuMouchel's RGPS analysis showing 49 examples of extreme masking with senior FDA officials.

Niu forwards DuMouchel's analysis to Zinderman without Szarfman; Zinderman flags it as worth considering.

Baer welcomes DuMouchel's input; Menschik pushes back on reaching out to Szarfman directly.

Szarfman shares DuMouchel's RGPS analysis revealing six new statistically significant safety signals.

Baer reports to colleagues that Szarfman offered to show Commonwealth her VAERS analysis; Niu distances herself.

Szarfman resends RGPS analysis flagging cardiac signals; Niu tells her CBER cannot collaborate.

Szarfman shares an EB data mining analysis; Niu confirms to Menschik she is not collaborating.

Zinderman directs Szarfman to hold off on creating COVID-19 vaccine data mining reports and analyses.

Szarfman tells Commonwealth contractor that the 20-year-old MGPS model could potentially mask signals.

Menschik tells Szarfman that VAERS data mining is CBER's responsibility and discussions must stay in chain of command.

Zinderman sends what records suggest is FDA's final weekly COVID-19 vaccine data mining report.

FDA officials discuss the masking effect three years after Szarfman raised it; Baer points to her published paper.